We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Read MoreHide Full Article
Alexion Pharmaceuticals, Inc.’s second-quarter 2016 earnings (including stock-based compensation expense) of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents. Earnings were, however, lower than the year-ago figure of $1.13.
Alexion’s revenues, on the other hand, soared 18.3% year over year to $753 million. The impact of currency headwinds on the top line was 3% ($18 million). The majority of the company’s revenues were generated by Soliris. The top line also surpassed the Zacks Consensus Estimate of $743 million.
Soliris Drives Growth
Soliris sales were up 10.2% to $701 million driven by steady growth in patients for both the approved indications – paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Sales volumes of Soliris were up 15% year over year.
Strensiq and Kanuma contributed $45 million and $6 million, respectively, to quarterly revenues.
Operating expenses (including stock-based compensation expense, and upfront and milestone payments related to license and collaboration deals, and other special items) were on the rise. Research and development (R&D) expenses were up 36.2%, while selling, general and administrative (SG&A) expenses rose 4.7%.
Outlook
Alexion has reiterated its guidance for total revenue and Soliris sales for 2016. The company continues to expect revenues in the range of $3.05–$3.1 billion, with Soliris contributing in the range of $2.83–$2.87 billion.
The company expects adjusted earnings per share in the range of $4.50–$4.65 (previous projection: at the low end of the $5.00–$5.20 band).
Revenues from the metabolic franchise, comprising Kanuma and Strensiq, are now expected in the range $200–$220 million ($180–$200 million expected previously). The company continues to expect R&D and SG&A expenses to be at the high end of the $650–$680 million band and the $760–$790 million band, respectively.
The company continues to progress on the candidates in its pipeline. Currently, the company is evaluating Soliris in three phase III studies – REGAIN, for the treatment of refractory generalized myasthenia gravis; PREVENT, for the treatment of relapsing neuromyelitis optica spectrum disorder; and PROTECT, for the treatment of delayed graft function. Results from the PROTECT study are expected in the second half of 2016.
Our Take
Alexion’s second-quarter results were impressive, with the company beating both top- and bottom-line estimates. We expect growth at Alexion to continue being driven by strong sales of Soliris. Launch of new products – Strensiq and Kanuma – should boost revenues and eventually reduce the company’s dependence on Soliris for growth. We are also impressed by Alexion’s efforts to develop its pipeline.
Alexion currently carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in the health care sector include Innoviva, Inc. (INVA - Free Report) , Nektar Therapeutics (NKTR - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
(We have revised this article to correct a mistake. The previous version, published earlier today, should not be relied upon).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Alexion Pharmaceuticals, Inc.’s second-quarter 2016 earnings (including stock-based compensation expense) of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents. Earnings were, however, lower than the year-ago figure of $1.13.
Alexion’s revenues, on the other hand, soared 18.3% year over year to $753 million. The impact of currency headwinds on the top line was 3% ($18 million). The majority of the company’s revenues were generated by Soliris. The top line also surpassed the Zacks Consensus Estimate of $743 million.
Soliris Drives Growth
Soliris sales were up 10.2% to $701 million driven by steady growth in patients for both the approved indications – paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Sales volumes of Soliris were up 15% year over year.
Strensiq and Kanuma contributed $45 million and $6 million, respectively, to quarterly revenues.
Operating expenses (including stock-based compensation expense, and upfront and milestone payments related to license and collaboration deals, and other special items) were on the rise. Research and development (R&D) expenses were up 36.2%, while selling, general and administrative (SG&A) expenses rose 4.7%.
Outlook
Alexion has reiterated its guidance for total revenue and Soliris sales for 2016. The company continues to expect revenues in the range of $3.05–$3.1 billion, with Soliris contributing in the range of $2.83–$2.87 billion.
The company expects adjusted earnings per share in the range of $4.50–$4.65 (previous projection: at the low end of the $5.00–$5.20 band).
Revenues from the metabolic franchise, comprising Kanuma and Strensiq, are now expected in the range $200–$220 million ($180–$200 million expected previously). The company continues to expect R&D and SG&A expenses to be at the high end of the $650–$680 million band and the $760–$790 million band, respectively.
ALEXION PHARMA Price
ALEXION PHARMA Price | ALEXION PHARMA Quote
Pipeline Update
The company continues to progress on the candidates in its pipeline. Currently, the company is evaluating Soliris in three phase III studies – REGAIN, for the treatment of refractory generalized myasthenia gravis; PREVENT, for the treatment of relapsing neuromyelitis optica spectrum disorder; and PROTECT, for the treatment of delayed graft function. Results from the PROTECT study are expected in the second half of 2016.
Our Take
Alexion’s second-quarter results were impressive, with the company beating both top- and bottom-line estimates. We expect growth at Alexion to continue being driven by strong sales of Soliris. Launch of new products – Strensiq and Kanuma – should boost revenues and eventually reduce the company’s dependence on Soliris for growth. We are also impressed by Alexion’s efforts to develop its pipeline.
Alexion currently carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in the health care sector include Innoviva, Inc. (INVA - Free Report) , Nektar Therapeutics (NKTR - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
(We have revised this article to correct a mistake. The previous version, published earlier today, should not be relied upon).